Changzhou Qianhong Bio-pharma Co. Ltd., a Chinese biopharmaceutical products manufacturer, has begun the construction of second phase of its pharmaceuticals production facility at Changzhou National Hi-Tech District.

With a commitment of 1 billion yuan ($145.3 million), phase two adds 200 million tablets and 60 million injections to production as well as making molecular diagnosis reagents available for use by 20 million people.

Phase two, consistent with international standards, will target the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights.

The 1.2 billion yuan phase one scheme, which is already in operation, generated sales revenue of  $155.4 million in 2017.